Publications by authors named "Elizabeth F Halton"

Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation and Stress Index) score (lactate dehydrogenase [LDH; U/L] × creatinine [mg/dL]/platelets [PLTs; 109 cells/L]) is a marker of endothelial damage that correlates with outcomes in allogeneic hematopoietic cell transplantation. Elevated LDH and low PLTs have been associated with severe CRS and ICANS, as has C-reactive protein (CRP), while increased creatinine is seen only in a minority of advanced severe CRS cases.

View Article and Find Full Text PDF
Article Synopsis
  • CD19-targeted CAR T-cell therapy is an effective treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), but most adult patients eventually progress after the initial response, with data on post-therapy outcomes lacking.* -
  • In a study of 38 adult patients, the median time to progression after CAR T therapy was 5.5 months and median survival post-progression was 7.5 months, with high disease burden at infusion correlating to a greater risk of progression.* -
  • Although the overall prognosis is poor, 43% of patients receiving salvage treatments, like blinatumomab and inotuzumab, achieved complete remission; new therapies are needed to
View Article and Find Full Text PDF

Various grading systems are currently used for chimeric antigen receptor (CAR) T-cell-related toxicity, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). We compared the recently proposed American Society for Transplantation and Cellular Therapy (ASTCT) grading system to other grading scores in 2 populations of adults: patients (n = 53) with B-cell acute lymphoblastic leukemia (B-ALL) treated with 1928z CAR T-cells (clinicaltrials.gov #NCT01044069), and patients (n = 49) with diffuse large B-cell lymphoma (DLBCL) treated with axicabtagene-ciloleucel (axi-cel) or tisagenlecleucel after US Food and Drug Administration approval.

View Article and Find Full Text PDF